| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -252,060 | -151,760 | -112,030 | -100,780 | -79,210 |
| Net Income Growth | -66.09% | -35.46% | -11.16% | -27.23% | -81.01% |
Akero Therapeutics Inc (AKRO)
45.12 +0.04 (+0.09%) 15:51 ET [NASDAQ]
45.11 x 103 45.19 x 15
Realtime by (Cboe BZX)
45.11 x 103 45.19 x 15
Realtime 45.18 +0.10 (+0.22%) 08:43 ET
for Tue, Mar 25th, 2025
Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States.
Fiscal Year End Date: 12/31